The company's strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. MannKind Corporation has completed its acquisition of scPharmaceuticals, with scPharmaceuticals showing impressive revenue growth of 107.79% over the last twelve months.
Cyborg Score Rationale
The company demonstrated strong revenue growth of 107.79% over the last twelve months. However, scPharmaceuticals became a wholly owned subsidiary of MannKind and is being delisted from the Nasdaq Global Select Market, indicating a transition to private status post-acquisition.
Top Insights
MannKind Corporation completed its acquisition of scPharmaceuticals in October 2025.
Company maintained a healthy current ratio of 3.85, indicating strong short-term liquidity position.
Focus on converting IV therapies to subcutaneous delivery with FUROSCIX as lead commercial product.
The acquisition reflected a 36% premium to scPharmaceuticals' 90-day volume-weighted average price.
Named Competitors
Subcutaneous Delivery Devices — Alternative IV-to-subcutaneous conversion technologies
Recent Developments
(October 2025) MannKind completed acquisition of scPharmaceuticals
(October 2025) Stock delisted from NASDAQ Global Select Market
(October 2025) Form 15 filed to terminate SEC registration
Open the full interactive scPharmaceuticals Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.